Paper Details

  1. Home
  2. Paper Details

Failure of tibolone to potentiate the pharmacological effect of fluoxetine in postmenopausal major depression.

Author: AlvaGuadalupe, BerlangaCarlos, MendietaDanelia, del Carmen LaraMaría

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

The gonadomimetic drug tibolone was investigated for its potential antidepressant effects in perimenopausal women.
Paper Details　
Original Abstract of the Article :
Perimenopausal depression has been attributed to physiological progressive estrogen decline. Estrogen and derivatives have some mood-enhancing effects, although studies of using estrogen as an antidepressant have had mixed results. The gonadomimetic drug tibolone stimulates estrogen receptors in a t...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1089/154099903321154121

データ提供：米国国立医学図書館（NLM）

Tibolone and Fluoxetine: A Search for Synergistic Effects in Postmenopausal Depression

Navigating the vast desert of postmenopausal depression, researchers are constantly searching for effective treatments. This study investigates the potential for tibolone, a gonadomimetic drug, to enhance the antidepressant effects of fluoxetine. Tibolone, known for its tissue-selective estrogenic activity, has been explored as a potential mood-enhancing agent. However, the use of estrogen as an antidepressant has yielded mixed results. This study aims to shed light on the potential synergistic effects of tibolone and fluoxetine in treating postmenopausal depression.

Tibolone's Limited Impact on Fluoxetine's Efficacy

This study found that tibolone failed to potentiate the pharmacological effects of fluoxetine in postmenopausal depression. This suggests that tibolone may not be a suitable adjunct to fluoxetine in treating this specific condition. The study emphasizes the need for further research to understand the complex interplay of hormones and antidepressants in the treatment of postmenopausal depression.

Navigating the Shifting Sands of Depression Treatment

The study highlights the challenges of treating postmenopausal depression. It demonstrates the need for careful consideration of treatment options and the importance of finding effective and safe approaches tailored to individual needs. It's a reminder that the desert of depression can be complex, requiring a nuanced and personalized approach to find the right path to recovery.

Dr.Camel's Conclusion

This research serves as a reminder that the desert of depression treatment is vast and complex. While tibolone may not be the answer for all cases of postmenopausal depression, it encourages continued exploration of novel treatments for this challenging condition. Further research is needed to uncover the intricate mechanisms underlying depression and to develop effective treatment strategies for all those navigating this challenging landscape.

Date :
  1. Date Completed 2003-06-26
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

12639367

DOI: Digital Object Identifier

10.1089/154099903321154121

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.